Novartis to shed three division heads in midst of Glaxo, Lilly deal prep

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Novartis to shed three division heads in midst of Glaxo, Lilly deal prep

Three division heads of Novartis ($NVS) will leave the company after transactions with GlaxoSmithKline ($GSK) and Eli Lilly ($LLY). George Gunn, now head of Novartis Animal Health, plans to retire in July 2015. Brian McNamara, head of Novartis OTC, will move to GSK as head of Americas and Europe for the consumer health businesses. Andrin Oswald, head of Novartis Vaccines, will be leaving Novartis to pursue other opportunities. Story

Novartis
Andrin Oswald is leaving as head of the vaccines unit.


NEA
Carol Gallagher joined the VC investment team.

Biotech

> Carol Gallagher has joined one of the world's largest VCs, accepting a position at New Enterprise Associates (NEA) to help nurture the next generation of disruptive biotechs. Story

> Brett Williams will succeed Kirk Schroeder as president of Essen Bioscience. Release

> Celsion ($CLSN) announced that the board of directors has appointed Michael H. Tardugno, the company's president and CEO, to the additional position of executive chairman of the board. Release

> Transgene has appointed Eric Quémeneur as executive vice president, vice president of research & development. Release

> Retrophin ($RTRX) has appointed Gary Lyons to its board of directors. Release

> Robert Lutz has joined Cortendo as the company's chief business officer. Release

> PDL BioPharma appointed Danny Hart as vice president of business development and Nathan Kryszak as senior counsel. Release

> Premier Biomedical named Dr. Patricio Reyes as a member of its scientific advisory board. Release

> Cynapsus hired Thierry Bilbault as its chief scientific officer and its executive vice president of chemistry, manufacturing and controls. Release

Pharma

> Pamela Strode joined Cerulean Pharma ($CERU) as its vice president of regulatory affairs. Release

> Allergan ($AGN) CEO David Pyott resigned from the board of directors at Edwards Lifesciences ($EW). Release

> New Haven Pharmaceuticals has appointed Dr. Jeffrey Patrick as chief scientific officer and Michael Richardson as chief business officer. Release

> Alexion Pharmaceuticals ($ALXN) has appointed Dr. Leonard Bell as chairman of its board of directors. Bell will continue to serve as the company's chief executive. Release

> Jefferson Gregory has joined Mezzion Pharma's board of directors. Release

> Angiotech Pharmaceuticals ($ANPI) has appointed John Barr as its chief executive officer. Release

> Aerie Pharmaceuticals ($AERI) elected Benjamin McGraw to its board of directors. Release

> Karen Flynn joined West Pharmaceutical ($WST) as president of the company's pharmaceutical packaging systems arm. Release

> Aeterna Zentaris ($AEZS) appointed Phil Theodore as chief administrative officer, general counsel and corporate secretary. Release

> SRI International named Michael Page as its vice president of information technology services and its chief information officer. Release

> Cary Claiborne left Sucampo Pharmaceuticals' ($SCMP) CFO position. Release

CRO

Adam Chasse has been appointed president of RxTrials. Release

Vaccines

> Dynavax's ($DVAX) board of directors announced that Dino Dina resigned from its board of directors. Release

Biotech Research

> The Diabetes Research Institute appointed Barbara Tavrow as its senior vice president. Release

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.